Latest Licensing And Royalties News

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

TG Metals has lodged a provisional patent application for a new technology that significantly improves lithium recovery and concentrate quality at its Burmeister deposit in Western Australia.

Metallium Ltd has revealed significant progress in commercialising its Flash Joule Heating technology with a new Texas facility and key partnerships, setting the stage for global expansion in critical metals recovery.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Metallium Ltd has raised A$50 million to accelerate the commercial launch of its patented Flash Joule Heating technology in the U.S., aiming to revolutionize strategic metal recovery from waste and ore. The company is set to commission its first commercial plant in Texas by early 2026, backed by key partnerships and strong institutional support.

Anagenics Limited’s licensed brand Bouf Haircare is outperforming expectations with strong early sales and promising royalty returns, signaling robust growth potential for the company’s intellectual property portfolio.

Hazer Group unveils a strategic alliance with engineering giant KBR to fast-track its low-cost clean hydrogen technology, targeting major global markets with a capex-lite licensing model.

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.